Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HS-20094 in Type 2 Diabetes
NCT06901648Phase 2Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2024
- Primary completion
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of olatorepatide in type 2 diabetes mellitus (T2DM), sponsored by Hansoh Pharmaceutical Group. Started Feb 2024; status: completed.
02
Drugs
olatorepatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06901648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901648.